Jane Street Group, LLC Blueprint Medicines Corp Transaction History

Jane Street Group, LLC

$481 Billion
Q2 2025

A detailed history of Jane Street Group, LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Jane Street Group, LLC holds 214,394 shares of BPMC stock, worth $27.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

214,394

Previous 375,818 42.95%

Holding current value

$27.8 Million

Previous $33.3 Million 17.38%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$79.22 - $128.4 $12.8 Million - $20.7 Million	-161,424 Reduced 42.95%	214,394 $27.5 Million
Q1 2025 May 14, 2025	SELL	$86.69 - $115.63 $2.81 Million - $3.75 Million	-32,404 Reduced 7.94%	375,818 $33.3 Million
Q4 2024 Feb 14, 2025	BUY	$82.48 - $101.39 $18.1 Million - $22.2 Million	219,085 Added 115.83%	408,222 $35.6 Million
Q3 2024 Nov 14, 2024	BUY	$84.1 - $120.5 $3.93 Million - $5.64 Million	46,780 Added 32.86%	189,137 $17.5 Million
Q2 2024 Aug 14, 2024	SELL	$85.18 - $108.78 $2.16 Million - $2.76 Million	-25,349 Reduced 15.12%	142,357 $15.3 Million
Q1 2024 May 15, 2024	BUY	$73.17 - $99.79 $4.93 Million - $6.72 Million	67,334 Added 67.08%	167,706 $15.9 Million
Q4 2023 Feb 14, 2024	BUY	$43.96 - $92.84 $3.66 Million - $7.73 Million	83,273 Added 487.01%	100,372 $9.26 Million
Q3 2023 Nov 14, 2023	SELL	$46.9 - $66.0 $2.68 Million - $3.78 Million	-57,243 Reduced 77.0%	17,099 $858,000
Q2 2023 Aug 14, 2023	BUY	$42.2 - $66.37 $409,424 - $643,921	9,702 Added 15.01%	74,342 $4.7 Million
Q1 2023 May 15, 2023	SELL	$37.97 - $50.0 $311,847 - $410,650	-8,213 Reduced 11.27%	64,640 $2.91 Million
Q4 2022 Feb 14, 2023	BUY	$41.06 - $66.48 $2.05 Million - $3.31 Million	49,852 Added 216.74%	72,853 $3.19 Million
Q3 2022 Nov 14, 2022	SELL	$49.93 - $77.7 $410,873 - $639,393	-8,229 Reduced 26.35%	23,001 $1.52 Million
Q2 2022 Aug 16, 2022	BUY	$45.23 - $70.15 $1.25 Million - $1.94 Million	27,613 Added 763.42%	31,230 $1.58 Million
Q1 2022 May 17, 2022	SELL	$54.1 - $110.08 $180,694 - $367,667	-3,340 Reduced 48.01%	3,617 $231,000
Q4 2021 Feb 15, 2022	SELL	$94.25 - $115.99 $2.57 Million - $3.16 Million	-27,270 Reduced 79.67%	6,957 $745,000
Q3 2021 Nov 16, 2021	BUY	$80.98 - $109.47 $1.54 Million - $2.09 Million	19,049 Added 125.5%	34,227 $3.52 Million
Q2 2021 Aug 16, 2021	SELL	$82.78 - $101.0 $461,001 - $562,469	-5,569 Reduced 26.84%	15,178 $1.34 Million
Q4 2020 Feb 17, 2021	SELL	$92.08 - $124.48 $752,109 - $1.02 Million	-8,168 Reduced 28.25%	20,747 $2.33 Million
Q3 2020 Nov 17, 2020	BUY	$66.45 - $92.7 $1.49 Million - $2.08 Million	22,426 Added 345.6%	28,915 $2.68 Million
Q2 2020 Aug 17, 2020	SELL	$57.09 - $79.27 $199,872 - $277,524	-3,501 Reduced 35.05%	6,489 $506,000
Q1 2020 May 15, 2020	SELL	$48.11 - $82.22 $3.2 Million - $5.47 Million	-66,570 Reduced 86.95%	9,990 $584,000
Q4 2019 Feb 14, 2020	BUY	$66.73 - $82.59 $3.01 Million - $3.73 Million	45,133 Added 143.61%	76,560 $6.13 Million
Q3 2019 Nov 14, 2019	SELL	$72.9 - $101.41 $72,389 - $100,700	-993 Reduced 3.06%	31,427 $2.31 Million
Q2 2019 Aug 15, 2019	BUY	$73.54 - $97.8 $1.44 Million - $1.91 Million	19,542 Added 151.75%	32,420 $3.06 Million
Q1 2019 May 16, 2019	BUY	$48.7 - $86.6 $627,158 - $1.12 Million	12,878 New	12,878 $1.03 Million
Q3 2018 Nov 14, 2018	SELL	$58.91 - $78.32 $191,221 - $254,226	-3,246 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$60.96 - $101.18 $197,876 - $328,430	3,246 New	3,246 $206,000
Q4 2017 Feb 15, 2018	SELL	$62.91 - $88.32 $1.08 Million - $1.52 Million	-17,204 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $728,933 - $1.2 Million	17,204	17,204 $1.2 Million

Others Institutions Holding BPMC

# of Institutions

390

Shares Held

66.9M

Call Options Held

973K

Put Options Held

1.54M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $7.73B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Blueprint Medicines Corp Transaction History